Tavneos is owned by Chemocentryx.
Tavneos contains Avacopan.
Tavneos has a total of 3 drug patents out of which 0 drug patents have expired.
Tavneos was authorised for market use on 07 October, 2021.
Tavneos is available in capsule;oral dosage forms.
Tavneos can be used as an adjunctive treatment of adult patients with tavneos (avacopan) with severe active anca-associated vasculitis (gpa and mpa) in combination with standard therapy including glucocorticoids.
Drug patent challenges can be filed against Tavneos from 2025-10-07.
The generics of Tavneos are possible to be released after 29 May, 2041.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US8906938||CHEMOCENTRYX||C5aR antagonists|| |
(6 years from now)
|US8445515||CHEMOCENTRYX||C5aR antagonists|| |
(7 years from now)
|US11603356||CHEMOCENTRYX||Amorphous form of a complement component C5a receptor|| |
(17 years from now)
|Orphan Drug Exclusivity (ODE)||Oct 7, 2028|
|New Chemical Entity Exclusivity (NCE)||Oct 7, 2026|
Drugs and Companies using AVACOPAN ingredient
NCE-1 date: 2025-10-07
Market Authorisation Date: 07 October, 2021
Treatment: An adjunctive treatment of adult patients with tavneos (avacopan) with severe active anca-associated vasculitis (gpa and mpa) in combination with standard therapy including glucocorticoids
Korea, Republic of
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic